Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A comprehensive genomic study of pediatric malignancy

ABSTRACT: A comprehensive genomic study of pediatric malignancy

PROVIDER: PRJNA588314 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR11021312_1.fastq.gz	Fastqsanger.gz
	SRR11021312_2.fastq.gz	Fastqsanger.gz
	SRR11021313_1.fastq.gz	Fastqsanger.gz
	SRR11021313_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 41

Similar Datasets

A comprehensive genomic study of pediatric malignancy

Project description:A comprehensive genomic study of pediatric malignancy

| PRJNA588315 | ENA

Genomic analysis of pediatric AML by whole transcriptome sequencing [pediatric AML patients]

Project description:Pediatric AML is an aggressive hematological malignancy associated with distinctive genomic features. We employed RNA-seq to study fusion genes and clinically relevant gene expression patterns in pediatric AML patients.

2023-05-02 | GSE222814 | GEO

Pediatric Reporting of Adult-Onset Genomic Results

Project description:The Investigators will conduct a longitudinal, mixed-methods cohort study to assess primary and secondary psychosocial outcomes among 705 MyCode pediatric participants and their parents, and health behaviors of parents whose children receive an adult- or pediatric-onset genomic result. Data will be gathered via quantitative surveys using validated measures of distress, family functioning, quality of life, body image, perceived cancer/heart disease risk, genetic counseling satisfaction, genomics knowledge, and adjustment to genetic information; qualitative interviews with adolescents and parents; and electronic health records review of parents’ cascade testing uptake and initiation of risk reduction behaviors. The investigators will also conduct empirical and theoretical legal research to examine the loss of chance doctrine and its applicability to genomic research.

| 2296574 | ecrin-mdr-crc

Genomic sequencing of Pediatric Rhabdomyosarcoma

Project description:Genomic sequencing of Pediatric Rhabdomyosarcoma

| PRJNA238611 | ENA

eMERGE Pediatric Study at CHB

Project description:eMERGE Pediatric Study at CHB

| PRJNA160299 | ENA

eMERGE Pediatric Study at CCHMC

Project description:eMERGE Pediatric Study at CCHMC

| PRJNA160057 | ENA

Gene expression of pediatric brain tumors- medulloblastoma and ependymoma

Project description:The aim of the study was to compare the level of gene expression in pediatric brain tumors of various degrees of malignancy.

2024-07-28 | E-MTAB-14259 | biostudies-arrayexpress

Genomic Sequencing of Pediatric Rhabdoid Cancers

Project description:Genomic Sequencing of Pediatric Rhabdoid Cancers

| PRJNA169040 | ENA

Pediatric Cardiac Genomics Consortium (PCGC) Study

Project description:Pediatric Cardiac Genomics Consortium (PCGC) Study

| PRJNA339492 | ENA

The genomic landscape of pediatric T-cell acute lymphoblastic leukemia reveals novel X-linked somatic mutations associated with apoptosis resistance. [RNA-Seq]

Project description:Background. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a dismal prognosis. It represents 15% of pediatric ALL and has a threefold higher incidence among males. T-cell transformation is a multi-step process involving cooperating events leading to altered T-cell signaling, proliferation, differentiation and survival. Many recurrent alterations have been identified and help define molecular subgroups of T-ALL, however the full range of events involved in driving transformation remain to be defined. Results. Using an integrative approach combining genomic and transcriptomic data, we performed comprehensive molecular characterization of 30 pediatric T-ALLs. We identified common T-ALL targets and confirmed the overall poor outcome of early immature cases. We also showed that deletion of the CDKN2A locus is associated with lower risk of relapse. In addition, we identified novel T-ALL drivers including a member of the spliceosome machinery U2AF1 as well as novel X-linked tumor suppressors MED12 and USP9X, that had never been associated to T-ALL before. Interestingly, almost 60% of these events were found in early immature cases which represented only 35% of the cohort. Functional validations further demonstrated the putative role of these novel T-ALL genes in driving transformation by demonstrating the aberrant splicing provoked by U2AF1 p.R35L and the protective effect against apoptosis of MED12 and USP9X repression. Conclusions. This study highlights the underlying genomic complexity of pediatric T-ALL, and the need for larger integrative studies to decipher the mechanisms that contribute to its various subtypes and provide opportunities to refine patient stratification and treatment.

2016-03-02 | GSE78785 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data